Morning Glory Sciences (@MorningGlorySci): "Finale is live: what’s next for CAC—GDF15 blockade, inflammation targets, and phenotype-driven trials. #Cachexia #Oncology https://www.morningglorysciences.com/en/series-decoding-cancer-associated-cachexia-from-basics-to-breakthroughs-part6-finale/" | ab4n

Morning Glory Sciences @MorningGlorySci

Nov 5

Finale is live: what’s next for CAC—GDF15 blockade, inflammation targets, and phenotype-driven trials. #Cachexia #Oncology morningglorysciences.com/en/…

Series: Decoding Cancer-Associated Cachexia — From Basics to Breakthroughs | Part 6 (Finale) -...

Our finale focuses on near-future therapies and trial design. Beyond “weight,” we target phenotype × mechanism and build evidence that actually changes care.

morningglorysciences.com

Nov 5, 2025 · 10:42 PM UTC